also at techcrunch was 23andme ceo and cofounder anne wojoliki.enetic testing company is hoping to leverage its technology and a partnership with a pharma giant glaxosmithkline to develop new treatments and cures for some of the most devastating diseases. she told me why it is a dream close to her heart. anne: 23andme started with the data. so we said that drug discovery can fundamentally change if you have an incredible amount of data. and so the hypothesis we have is that if we have all of this information, and we discover targets that started from a human genetic component, that will have a higher success rate with drug development. so most drugs today when they are in development, they fail. the reason why it is so expensive to develop a drug is because 95% of everything fails. so if we can actually have a better beginning starting with human genetics, we believe we have a higher likelihood of succeeding. so the partnership with gs k is all about helping us scale the drug development process. so we can find tons and tons and tons of ideas. but